CL2007002658A1 - Compuestos derivados de purina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias. - Google Patents

Compuestos derivados de purina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.

Info

Publication number: CL2007002658A1
Authority: CL; Chile
Prior art keywords: compound; purina; inflammatory; treatment; pharmaceutical composition
Prior art date: 2006-09-14

Application number

CL200702658A

Other languages

English (en)

Inventor

Robin Alec Y Taylor Fairhurst

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-14

Filing date

2007-09-13

Publication date

2008-08-08

2007-09-13 Application filed by Novartis Ag filed Critical Novartis Ag

2008-08-08 Publication of CL2007002658A1 publication Critical patent/CL2007002658A1/es

Links

150000001875 compounds Chemical class 0.000 title 3
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
230000002757 inflammatory effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
230000000414 obstructive effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
230000000241 respiratory effect Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Hydrogenated Pyridines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

CL200702658A 2006-09-14 2007-09-13 Compuestos derivados de purina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias. CL2007002658A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06120706A EP1903044A1 (en)	2006-09-14	2006-09-14	Adenosine Derivatives as A2A Receptor Agonists

Publications (1)

Publication Number	Publication Date
CL2007002658A1 true CL2007002658A1 (es)	2008-08-08

Family

ID=37622170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702658A CL2007002658A1 (es)	2006-09-14	2007-09-13	Compuestos derivados de purina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.

Country Status (30)

Country	Link
US (1)	US8188100B2 (es)
EP (2)	EP1903044A1 (es)
JP (1)	JP2010503639A (es)
KR (1)	KR20090040386A (es)
CN (1)	CN101511831B (es)
AR (1)	AR062768A1 (es)
AT (1)	ATE481404T1 (es)
AU (1)	AU2007296227A1 (es)
BR (1)	BRPI0716936A2 (es)
CA (1)	CA2662104A1 (es)
CL (1)	CL2007002658A1 (es)
CR (1)	CR10621A (es)
CY (1)	CY1110990T1 (es)
DE (1)	DE602007009272D1 (es)
DK (1)	DK2066669T3 (es)
ES (1)	ES2353141T3 (es)
HR (1)	HRP20100694T1 (es)
IL (1)	IL197153A0 (es)
MA (1)	MA30722B1 (es)
MX (1)	MX2009002811A (es)
NO (1)	NO20091244L (es)
PE (1)	PE20081151A1 (es)
PL (1)	PL2066669T3 (es)
PT (1)	PT2066669E (es)
RU (1)	RU2009113668A (es)
SI (1)	SI2066669T1 (es)
TN (1)	TN2009000084A1 (es)
TW (1)	TW200821324A (es)
WO (1)	WO2008031875A1 (es)
ZA (1)	ZA200901036B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1434782A2 (en) *	2001-10-01	2004-07-07	University of Virginia Patent Foundation	2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
GT200500281A (es) *	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
US9512125B2 (en)	2004-11-19	2016-12-06	The Regents Of The University Of California	Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
GB0500785D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
WO2007120972A2 (en) *	2006-02-10	2007-10-25	University Of Virginia Patent Foundation	Method to treat sickle cell disease
WO2007114926A2 (en)	2006-04-04	2007-10-11	The Regents Of The University Of California	Kinase antagonists
GB0607944D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607950D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP2322525B1 (en) *	2006-04-21	2013-09-18	Novartis AG	Purine derivatives for use as adenosin A2A receptor agonists
GB0607953D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
US8188063B2 (en)	2006-06-19	2012-05-29	University Of Virginia Patent Foundation	Use of adenosine A2A modulators to treat spinal cord injury
WO2008000743A2 (en) *	2006-06-27	2008-01-03	Biovitrum Ab (Publ)	Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
EP1889846A1 (en)	2006-07-13	2008-02-20	Novartis AG	Purine derivatives as A2a agonists
CA2669108A1 (en) *	2006-11-10	2008-05-15	Novartis Ag	Cyclopentene diol monoacetate derivatives
GB2467670B (en)	2007-10-04	2012-08-01	Intellikine Inc	Chemical entities and therapeutic uses thereof
WO2009050199A1 (en) *	2007-10-17	2009-04-23	Novartis Ag	Purine derivatives as adenosine al receptor ligands
US8058259B2 (en)	2007-12-20	2011-11-15	University Of Virginia Patent Foundation	Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EP3613743B1 (en)	2008-01-04	2022-03-16	Intellikine, LLC	Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8637542B2 (en)	2008-03-14	2014-01-28	Intellikine, Inc.	Kinase inhibitors and methods of use
US8993580B2 (en)	2008-03-14	2015-03-31	Intellikine Llc	Benzothiazole kinase inhibitors and methods of use
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
JP5788316B2 (ja)	2008-07-08	2015-09-30	インテリカイン，エルエルシー	キナーゼインヒビターおよび使用方法
US8703778B2 (en)	2008-09-26	2014-04-22	Intellikine Llc	Heterocyclic kinase inhibitors
WO2010045542A2 (en)	2008-10-16	2010-04-22	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
EP2427195B1 (en)	2009-05-07	2019-05-01	Intellikine, LLC	Heterocyclic compounds and uses thereof
PE20121148A1 (es)	2009-08-17	2012-09-07	Intellikine Llc	Compuestos heterociclicos y usos de los mismos
US8980899B2 (en)	2009-10-16	2015-03-17	The Regents Of The University Of California	Methods of inhibiting Ire1
CA2799579A1 (en)	2010-05-21	2011-11-24	Intellikine, Inc.	Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja)	2010-11-10	2013-12-26	インフィニティーファーマシューティカルズ，インコーポレイテッド	複素環化合物及びその使用
TWI674262B (zh)	2011-01-10	2019-10-11	美商英菲尼提製藥股份有限公司	製備異喹啉酮之方法及異喹啉酮之固體形式
US9295673B2 (en)	2011-02-23	2016-03-29	Intellikine Llc	Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
WO2013012915A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
MX2014000648A (es)	2011-07-19	2014-09-25	Infinity Pharmaceuticals Inc	Compuestos heterociclicos y sus usos.
KR20140075693A (ko)	2011-08-29	2014-06-19	인피니티 파마슈티칼스, 인코포레이티드	헤테로사이클릭 화합물 및 그의 용도
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
MX2015003874A (es)	2012-09-26	2015-12-16	Univ California	Modulacion de ire1.
EP2914296B2 (en)	2012-11-01	2021-09-29	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
MX2021012208A (es)	2013-10-04	2023-01-19	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos y usos de los mismos.
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
NZ724368A (en)	2014-03-19	2023-07-28	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
CN105012318B (zh) *	2014-04-17	2020-02-11	沈华浩	磺酰胺类化合物在气道慢性炎症性疾病中的应用
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP4585268A3 (en)	2015-09-14	2025-10-15	Twelve Therapeutics, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CN109640987B (zh) *	2016-03-16	2022-12-02	库拉肿瘤学公司	Menin-mll的桥联双环抑制剂及使用方法
CN109152784B (zh)	2016-03-16	2021-12-28	库拉肿瘤学公司	经取代的menin-mll抑制剂及使用方法
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
RU2754507C2 (ru)	2016-06-24	2021-09-02	Инфинити Фармасьютикалз, Инк.	Комбинированная терапия
CN110691779B (zh)	2017-03-24	2023-10-10	库拉肿瘤学公司	治疗血液系统恶性肿瘤和尤因肉瘤的方法
US11542248B2 (en)	2017-06-08	2023-01-03	Kura Oncology, Inc.	Methods and compositions for inhibiting the interaction of menin with MLL proteins
US11649251B2 (en)	2017-09-20	2023-05-16	Kura Oncology, Inc.	Substituted inhibitors of menin-MLL and methods of use
US11312715B2 (en)	2017-09-28	2022-04-26	Cstone Pharmaceuticals (Suzhou) Co., Ltd.	Fused ring derivative as A2A receptor inhibitor
CN113194752A (zh)	2018-06-01	2021-07-30	康奈尔大学	Pi3k相关疾病或病症的组合疗法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1528382A (en) *	1974-12-26	1978-10-11	Teijin Ltd	Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) *	1985-11-06	1988-04-19	Warner-Lambert Company	Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) *	1986-07-10	1989-10-10	Board Of Governors Of Wayne State University	Process for the preparation of cyclopentanoids and novel intermediates produced thereby
US4954504A (en) *	1986-11-14	1990-09-04	Ciba-Geigy Corporation	N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
IL84414A0 (en)	1986-11-14	1988-04-29	Ciba Geigy Ag	N9-cyclopentyl-substituted adenine derivatives
JP2586897B2 (ja)	1987-03-09	1997-03-05	富士薬品工業株式会社	光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
SG80526A1 (en)	1990-09-25	2001-05-22	Rhone Poulenc Rorer Int	Compounds having antihypertensive and anti- ischemic properies
IT1254915B (it)	1992-04-24	1995-10-11	Gloria Cristalli	Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) *	1993-07-13	1997-11-18	The United States Of America As Represented By The Department Of Health And Human Services	A3 adenosine receptor agonists
US5691188A (en) *	1994-02-14	1997-11-25	American Cyanamid Company	Transformed yeast cells expressing heterologous G-protein coupled receptor
EA000884B1 (ru) *	1996-01-02	2000-06-26	Рон-Пуленк Рорер Фармасьютикалз Инк.	Способ получения 2,4-дигидроксипиридина и 2,4-дигидрокси-3-нитропиридина
US6376472B1 (en) *	1996-07-08	2002-04-23	Aventis Pharmaceuticals, Inc.	Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
AU750322B2 (en) *	1997-05-09	2002-07-18	Trustees Of The University Of Pennsylvania, The	Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB9813540D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813554D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813535D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
AU750462B2 (en)	1998-06-23	2002-07-18	Glaxo Group Limited	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AU5879299A (en)	1998-10-16	2000-05-08	Monaghan, Sandra Marina	Adenine derivatives
CN1383427A (zh) *	1998-12-31	2002-12-04	阿温蒂斯药物公司	制备n6－取代的脱氮杂一腺苷衍生物的方法
US7427606B2 (en) *	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en)	1999-06-18	2001-11-27	University Of Virginia Patent Foundation	Induction of pharmacological stress with adenosine receptor agonists
US6403567B1 (en)	1999-06-22	2002-06-11	Cv Therapeutics, Inc.	N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) *	1999-06-22	2001-04-10	Cv Therapeutics, Inc.	C-pyrazole 2A A receptor agonists
US6586413B2 (en) *	1999-11-05	2003-07-01	The United States Of America As Represented By The Department Of Health And Human Services	Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
JP4012070B2 (ja)	2001-01-16	2007-11-21	カン−フィテ・バイオファーマ・リミテッド	ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
GB2372741A (en)	2001-03-03	2002-09-04	Univ Leiden	C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) *	2001-03-20	2004-08-19	Adrian Hall	Chemical compounds
EP1258247A1 (en) *	2001-05-14	2002-11-20	Aventis Pharma Deutschland GmbH	Adenosine analogues for the treatment of insulin resistance syndrome and diabetes
EP1434782A2 (en)	2001-10-01	2004-07-07	University of Virginia Patent Foundation	2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
US7414036B2 (en) *	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
AU2003234716A1 (en)	2002-04-10	2003-10-27	Joel M. Linden	Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
DE602004006895T2 (de) *	2003-12-29	2008-01-31	Can-Fite Biopharma Ltd.	Verfahren zur behandlung von multipler sklerose
CA2557285A1 (en)	2004-03-05	2005-09-15	Cambridge Biotechnology Limited	Adenosine receptor agonists
WO2005107463A1 (en)	2004-05-03	2005-11-17	University Of Virginia Patent Foundation	Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
AR049384A1 (es) *	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
EP1778239B1 (en)	2004-07-28	2013-08-21	Can-Fite Biopharma Ltd.	Adenosine a3 receptor agonists for the treatment of dry eye disorders including sjogren's syndrome
US7825102B2 (en) *	2004-07-28	2010-11-02	Can-Fite Biopharma Ltd.	Treatment of dry eye conditions
JP2008512457A (ja) *	2004-09-09	2008-04-24	アメリカ合衆国	Ａ３及びａ１アデノシン受容体作用薬としてのプリン誘導体
GT200500281A (es)	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
US20080051364A1 (en) *	2004-11-08	2008-02-28	Pninna Fishman	Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
RS52458B (sr) *	2005-02-04	2013-02-28	Millennium Pharmaceuticals Inc.	Inhibitori e1 aktivirajućih enzima
GB0505219D0 (en) *	2005-03-14	2005-04-20	Novartis Ag	Organic compounds
GB0514809D0 (en) *	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
JP5339916B2 (ja) *	2005-11-30	2013-11-13	キャン−ファイト・バイオファーマ・リミテッド	骨関節炎の治療におけるａ３アデノシン受容体アゴニストの使用
CN101410114B (zh) *	2006-01-26	2012-07-04	美国政府卫生与公共服务部	A3腺苷受体别构调节剂
EA024006B1 (ru) *	2006-02-02	2016-08-31	Миллениум Фармасьютикалз, Инк.	Ингибиторы е1 активирующих ферментов
WO2007092936A2 (en) *	2006-02-08	2007-08-16	University Of Virginia Patent Foundation	Method to treat gastric lesions
GB0607953D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607944D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607951D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607950D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP2322525B1 (en) *	2006-04-21	2013-09-18	Novartis AG	Purine derivatives for use as adenosin A2A receptor agonists
GB0607954D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607948D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607945D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP1889846A1 (en)	2006-07-13	2008-02-20	Novartis AG	Purine derivatives as A2a agonists
US8008307B2 (en) *	2006-08-08	2011-08-30	Millennium Pharmaceuticals, Inc.	Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CA2669108A1 (en) *	2006-11-10	2008-05-15	Novartis Ag	Cyclopentene diol monoacetate derivatives
WO2008124150A1 (en) *	2007-04-09	2008-10-16	University Of Virginia Patent Foundation	Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
US20080262001A1 (en) *	2007-04-23	2008-10-23	Adenosine Therapeutics, Llc	Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
EP2170401A1 (en) *	2007-06-29	2010-04-07	Government of the United States of America, Represented by the Secretary, Department of Health and Human Services	Dendrimer conjugates of agonists and antagonists of the gpcr superfamily
US20090181934A1 (en) *	2007-10-17	2009-07-16	Novartis Ag	Organic Compounds
WO2009050199A1 (en) *	2007-10-17	2009-04-23	Novartis Ag	Purine derivatives as adenosine al receptor ligands
WO2009061516A1 (en) *	2007-11-08	2009-05-14	New York University School Of Medicine	Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
JP2011509305A (ja) *	2008-01-09	2011-03-24	ピージーエックスヘルス、リミテッド、ライアビリティー、カンパニー	Ａ２ａｒアゴニストによる神経障害性疼痛の髄腔内治療

2006
- 2006-09-14 EP EP06120706A patent/EP1903044A1/en not_active Ceased
2007
- 2007-09-12 PE PE2007001224A patent/PE20081151A1/es not_active Application Discontinuation
- 2007-09-12 AR ARP070104040A patent/AR062768A1/es not_active Application Discontinuation
- 2007-09-13 PT PT07803477T patent/PT2066669E/pt unknown
- 2007-09-13 EP EP07803477A patent/EP2066669B1/en active Active
- 2007-09-13 DE DE602007009272T patent/DE602007009272D1/de active Active
- 2007-09-13 SI SI200730448T patent/SI2066669T1/sl unknown
- 2007-09-13 AU AU2007296227A patent/AU2007296227A1/en not_active Abandoned
- 2007-09-13 HR HR20100694T patent/HRP20100694T1/hr unknown
- 2007-09-13 CL CL200702658A patent/CL2007002658A1/es unknown
- 2007-09-13 ES ES07803477T patent/ES2353141T3/es active Active
- 2007-09-13 JP JP2009527828A patent/JP2010503639A/ja not_active Withdrawn
- 2007-09-13 CA CA002662104A patent/CA2662104A1/en not_active Abandoned
- 2007-09-13 MX MX2009002811A patent/MX2009002811A/es not_active Application Discontinuation
- 2007-09-13 WO PCT/EP2007/059666 patent/WO2008031875A1/en not_active Ceased
- 2007-09-13 RU RU2009113668/04A patent/RU2009113668A/ru unknown
- 2007-09-13 AT AT07803477T patent/ATE481404T1/de active
- 2007-09-13 KR KR1020097005251A patent/KR20090040386A/ko not_active Abandoned
- 2007-09-13 CN CN2007800333258A patent/CN101511831B/zh not_active Expired - Fee Related
- 2007-09-13 PL PL07803477T patent/PL2066669T3/pl unknown
- 2007-09-13 TW TW096134289A patent/TW200821324A/zh unknown
- 2007-09-13 US US12/310,254 patent/US8188100B2/en not_active Expired - Fee Related
- 2007-09-13 BR BRPI0716936-1A2A patent/BRPI0716936A2/pt not_active IP Right Cessation
- 2007-09-13 DK DK07803477.4T patent/DK2066669T3/da active
2009
- 2009-02-13 ZA ZA200901036A patent/ZA200901036B/xx unknown
- 2009-02-19 CR CR10621A patent/CR10621A/es not_active Application Discontinuation
- 2009-02-19 IL IL197153A patent/IL197153A0/en unknown
- 2009-03-13 TN TN2009000084A patent/TN2009000084A1/fr unknown
- 2009-03-25 NO NO20091244A patent/NO20091244L/no not_active Application Discontinuation
- 2009-03-30 MA MA31736A patent/MA30722B1/fr unknown
2010
- 2010-12-15 CY CY20101101154T patent/CY1110990T1/el unknown

Also Published As

Publication number	Publication date
KR20090040386A (ko)	2009-04-23
DK2066669T3 (da)	2011-01-10
ATE481404T1 (de)	2010-10-15
JP2010503639A (ja)	2010-02-04
RU2009113668A (ru)	2010-10-20
BRPI0716936A2 (pt)	2013-09-17
ES2353141T3 (es)	2011-02-25
PE20081151A1 (es)	2008-10-06
CN101511831B (zh)	2012-04-25
PT2066669E (pt)	2010-12-17
CR10621A (es)	2009-03-27
HK1131392A1 (en)	2010-01-22
CN101511831A (zh)	2009-08-19
TW200821324A (en)	2008-05-16
EP1903044A1 (en)	2008-03-26
CY1110990T1 (el)	2015-06-11
ZA200901036B (en)	2010-01-27
WO2008031875A1 (en)	2008-03-20
MA30722B1 (fr)	2009-09-01
SI2066669T1 (sl)	2011-01-31
AU2007296227A1 (en)	2008-03-20
US8188100B2 (en)	2012-05-29
MX2009002811A (es)	2009-03-31
NO20091244L (no)	2009-04-07
PL2066669T3 (pl)	2011-03-31
US20090325967A1 (en)	2009-12-31
DE602007009272D1 (de)	2010-10-28
TN2009000084A1 (en)	2010-08-19
EP2066669B1 (en)	2010-09-15
EP2066669A1 (en)	2009-06-10
HRP20100694T1 (hr)	2011-01-31
AR062768A1 (es)	2008-12-03
IL197153A0 (en)	2009-11-18
CA2662104A1 (en)	2008-03-20

Publication	Publication Date	Title
CL2007002658A1 (es)	2008-08-08	Compuestos derivados de purina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
CL2007001131A1 (es)	2008-07-11	Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
CL2007001132A1 (es)	2008-05-23	Compuestos derivados de purina sustituida con otros sistemas heterociclicos; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
CY2024007I2 (el)	2024-09-20	Γλυκοπυρανοζυλο-υποκατεστημενα παραγωγα βενζονιτριλιου, φαρμακευτικες συνθεσεις που περιεχουν τετοιες ενωσεις, η χρηση τους και μεθοδοι παρασκευης τους
CL2007002641A1 (es)	2008-06-20	Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2008001868A1 (es)	2008-10-17	Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
CL2007003192A1 (es)	2008-06-20	Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario.
CL2007003299A1 (es)	2008-08-22	Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008000127A1 (es)	2008-05-23	Compuestos derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, inflamacion, trastornos urologicos
CL2007001992A1 (es)	2008-07-18	Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2007002866A1 (es)	2008-07-04	Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008000946A1 (es)	2008-10-10	Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
CL2007001427A1 (es)	2008-05-16	Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
CL2007002018A1 (es)	2008-05-09	Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2007003797A1 (es)	2008-07-18	Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
CL2007002920A1 (es)	2008-06-06	Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007002578A1 (es)	2008-07-04	Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
CL2007002043A1 (es)	2008-06-13	Compuestos derivados de pirimidinas sustituidos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, hipertension pulmonar, fibrosis pulmonar, fibro
CL2008001273A1 (es)	2008-09-22	Compuestos derivados de heterociclos, inhibidores de proteina activadora de la 5-lipoxigenasa (flap); composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la inflamacion, enfermedad cardiovascular, asma
CL2007001630A1 (es)	2008-02-08	Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007002128A1 (es)	2008-04-18	Derivados de n'-ciano-n-halogenoalquil-imidamida; procedimiento para la preparacion de dicho compuesto; composiciones farmaceuticas que lo contienen; y uso del compuesto para combatir parasitos animales.